Pulmonx Q1 revenue $18.9M (+30% YoY); net loss narrows to $13.7M

Pulmonx Corp

2024-Q1 EPS reported -$0.36 revenue$18,854,000

Q1 revenue $18.9M, up 30% YoY (29% constant currency); U.S. revenue $12.9M (+38%).
Net loss $13.7M ($0.36 per share) versus $15.9M ($0.42) in Q1 2023; Adjusted EBITDA loss $8M vs $11.2M.
Gross margin 75% (vs 73% YoY); FY 2024 revenue guidance reaffirmed $81M-$84M; operating expenses guidance tightened to $127M-$129M.
Cash and equivalents $120.4M; clinical milestones: first AeriSeal CONVERT II patient and first Japanese Zephyr post-approval patient.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.